Encompass Health (EHC)
(Real Time Quote from BATS)
$84.14 USD
+0.93 (1.12%)
Updated May 6, 2024 01:44 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EHC 84.14 +0.93(1.12%)
Will EHC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EHC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EHC
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
EHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
Should Value Investors Buy Encompass Health (EHC) Stock?
Other News for EHC
Peering Into Encompass Health's Recent Short Interest
Encompass Health declares dividend on common stock
Encompass Health declares $0.15 dividend
Encompass Health opens request for grant applications
Encompass Health price target raised by $10 at Raymond James, here's why